INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Grant or awardVerified data

Bell John Irving reported IMCR

Director · Immunocore Holdings plc · Immunocore Holdings plc — Share Option (Right to Buy)

Side
A
Value
—
Shares
27.5K
Price
—
Executed
May 27, 2026
Disclosed
May 28, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
May 27 executedMay 28, 2026 disclosed

IMCR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IMCR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    KS
    Kaul SiddharthDirector
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    27.5K sh
    		May 27, 2026May 28, 2026
    traded May 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    PW
    Pao WilliamDirector
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    27.5K sh
    		May 27, 2026May 28, 2026
    traded May 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RJ
    Ratcliffe Peter JohnDirector
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    27.5K sh
    		May 27, 2026May 28, 2026
    traded May 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    HS
    Herbst Roy StevenDirector
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    27.5K sh
    		May 27, 2026May 28, 2026
    traded May 27, 2026
    		+1dSEC FORM 4

    Evidence

    34
    SA
    St Leger Tina AmberCHIEF HR OFFICER
    IMCRImmunocore Holdings plc
    Open-market sale
    		SELL$32K
    1,000 sh
    		Feb 18, 2026Feb 19, 2026
    traded Feb 18, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    St Leger Tina AmberCHIEF HR OFFICER
    IMCRImmunocore Holdings plc
    Option exercise
    		M—
    2,119 sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    21
    SA
    St Leger Tina AmberCHIEF HR OFFICER
    IMCRImmunocore Holdings plc
    Option exercise
    		M—
    2,119 sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CA
    Coy Travis AlanChief Financial Officer
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    33.4K sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CA
    Coy Travis AlanChief Financial Officer
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    95.6K sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    2
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise
    		M—
    11.8K sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    34
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Open-market sale
    		SELL$193K
    5,965 sh
    		Feb 18, 2026Feb 19, 2026
    traded Feb 18, 2026
    		+1dSEC FORM 4

    Evidence

    10
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise
    		M—
    11.8K sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    0
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M—
    572 sh
    		Dec 5, 2025Dec 8, 2025
    traded Dec 5, 2025
    		+3dSEC FORM 4

    Evidence

    13
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Open-market sale · 10b5-1 plan
    		SELL$23K
    572 sh
    		Dec 5, 2025Dec 8, 2025
    traded Dec 5, 2025
    		+3dSEC FORM 4

    Evidence

    0
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M$9,987
    572 sh
    		Dec 5, 2025Dec 8, 2025
    traded Dec 5, 2025
    		+3dSEC FORM 4

    Evidence

    22
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Open-market sale · 10b5-1 plan
    		SELL$1.26M
    31.3K sh
    		Dec 4, 2025Dec 8, 2025
    traded Dec 4, 2025
    		+4dSEC FORM 4

    Evidence

    1
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M$547K
    31.3K sh
    		Dec 4, 2025Dec 8, 2025
    traded Dec 4, 2025
    		+4dSEC FORM 4

    Evidence

    0
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M—
    31.3K sh
    		Dec 4, 2025Dec 8, 2025
    traded Dec 4, 2025
    		+4dSEC FORM 4

    Evidence

    10
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M$1.21M
    69.4K sh
    		Nov 26, 2025Dec 1, 2025
    traded Nov 26, 2025
    		+5dSEC FORM 4

    Evidence

    28
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Open-market sale · 10b5-1 plan
    		SELL$2.78M
    69.4K sh
    		Nov 26, 2025Dec 1, 2025
    traded Nov 26, 2025
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001969932-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 27, 2026
    Published
    May 28, 2026
    Ingested by INSIDER
    Nov 5, 03:56 UTC
    Last re-read
    Nov 5, 03:56 UTC

    Extracted facts

    Filer
    Bell John Irving
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Immunocore Holdings plc — Share Option (Right to Buy)
    Ticker
    IMCR
    Shares
    27.5K
    Price per share
    $0
    Execution date (reported)
    May 27, 2026
    Owned after transaction
    27.5K shares
    Days from execution to publication
    1

    What this establishes

    Bell John Irving filed this Form 4 reporting a grant or award of IMCR on May 27, 2026. It became public on May 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Bell John Irvingcik:0001969932
    Issuer
    Immunocore Holdings plccik:0001671927

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.